TIGIT, a novel immune checkpoint, plays a role in immune suppression and facilitates tumor immune evasion by inhibiting immune cell functions.[57] Notably, combining IL‐15 with TIGIT blockade can activate CD8+ TIL‐mediated anti‐tumor immunity in lung adenocarcinoma.[58] However, the role of TIGIT in the development and progression of MSS CRC remains unclear. Here, CD8A is linked to colorectal carcinoma.